Basic Description:

Pasireotide - SOM230 - Ongoing Trial - Not Accepting New Patients "Pasireotide (SOM230) is an orphan drug currently in phase III studies for the treatment of Cushing's disease. It was developed by Novartis. Pasireotide is a somatostatin analog which has a 40-fold increased affinity to somatostatin receptor 5 than other somatostatin analogs." - Wikipedia

NF2 Trial:

• Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma - www.ClinicalTrials.gov
• SOM230-C Trial - Meningiomas - PHASE II Study of Monthly SOM230 for Recurrent or Progressive Meningioma (IRB#19611) - Cedars-Sinai Medical Center / Cochran Brain Tumor Center

NF2 NYC Support Group, New York
Email: Lori Davila at lori@nf2nycsupport.org
Copyright © 2008 - 2012

DISCLAIMER: www.nf2nycsupport.org is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. While we hope the information found on the www.nf2nycsupport.org site is helpful in offering suggestions in topics to discuss with your doctor, information found here should not be considered actual medical advice. Medical advice should always be sought by consultation with a medical professional.